2ⁿᵈ Edition of the Cancer R&D World Conference 2026

Liquid biopsy is transforming cancer diagnostics by offering a non-invasive, real-time method to detect and monitor tumors through biomarkers found in body fluids such as blood. Among these, circulating tumor DNA (ctDNA) has emerged as a powerful tool for early detection, disease monitoring, and treatment response assessment. By capturing genetic alterations shed from tumors, ctDNA analysis enables clinicians to track tumor evolution, identify minimal residual disease, and guide precision therapy decisions. This approach minimizes the need for traditional tissue biopsies while providing dynamic insights into cancer progression.

This session will provide an overview of the state-of-the-art developments in liquid biopsy technologies and ctDNA profiling in the clinical arena at the Cancer Research and Development Conference 2026. The Clinical Oncology Congress serves as the go-to place for clinicians from community clinics and NCI-designated cancer centers who need the most recent guidelines and real-world clinical data. Experts will deliberate on various analytical challenges, discuss standardization efforts, and integration of liquid biopsy into personalized oncology care. Join us to understand how diagnostics based on ctDNA are transforming the diagnosis and management of cancers, thus opening avenues for earlier interventions and better patient outcomes.